Dash Acquisitions Inc. Buys Shares of 4,285 IDEXX Laboratories, Inc. $IDXX

Dash Acquisitions Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,285 shares of the company’s stock, valued at approximately $2,690,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $31,000. Armstrong Advisory Group Inc. increased its stake in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth about $35,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories during the second quarter valued at about $30,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 62.2% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 60 shares of the company’s stock valued at $38,000 after buying an additional 23 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of several analyst reports. BTIG Research lifted their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. UBS Group raised their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, January 12th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

IDEXX Laboratories Trading Up 0.4%

Shares of NASDAQ:IDXX opened at $693.85 on Friday. The firm has a fifty day moving average of $705.83 and a two-hundred day moving average of $654.72. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The firm has a market capitalization of $55.40 billion, a P/E ratio of 55.02, a price-to-earnings-growth ratio of 3.70 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the company earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.